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ARTICLE

Elevated gene expression of glutamate receptors
in noradrenergic neurons from the locus
coeruleus in major depression
Michelle J. Chandley1, Attila Szebeni1, Katalin Szebeni1, Jessica D. Crawford1,
Craig A. Stockmeier2, Gustavo Turecki3, Richard M. Kostrzewa1 and Gregory A. Ordway1
1

Department of Biomedical Sciences, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA
Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA
3
Department of Psychiatry, McGill University, Montreal, PQ, Canada
2

Glutamate receptors are promising drug targets for the treatment of urgent suicide ideation and chronic major
depressive disorder (MDD) that may lead to suicide completion. Antagonists of glutamatergic NMDA receptors
reduce depressive symptoms faster than traditional antidepressants, with beneﬁcial effects occurring within
hours. Glutamate is the prominent excitatory input to the noradrenergic locus coeruleus (LC). The LC is activated
by stress in part through this glutamatergic input. Evidence has accrued demonstrating that the LC may be overactive in MDD, while treatment with traditional antidepressants reduces LC activity. Pathological alterations of
both glutamatergic and noradrenergic systems have been observed in depressive disorders, raising the prospect
that disrupted glutamate-norepinephrine interactions may be a central component to depression and suicide
pathobiology. This study examined the gene expression levels of glutamate receptors in post-mortem noradrenergic LC neurons from subjects with MDD (most died by suicide) and matched psychiatrically normal controls.
Gene expression levels of glutamate receptors or receptor subunits were measured in LC neurons collected by
laser capture microdissection. MDD subjects exhibited signiﬁcantly higher expression levels of the NMDA receptor subunit genes, GRIN2B and GRIN2C, and the metabotropic receptor genes, GRM4 and GRM5, in LC neurons.
Gene expression levels of these receptors in pyramidal neurons from prefrontal cortex (BA10) did not reveal abnormalities in MDD. These ﬁndings implicate disrupted glutamatergic-noradrenergic interactions at the level of
the stress-sensitive LC in MDD and suicide, and provide a theoretical mechanism by which glutamate antagonists may exert rapid antidepressant effects.
Received 15 October 2013; Reviewed 18 November 2013; Revised 27 March 2014; Accepted 4 April 2014;
First published online 13 June 2014
Key words: Glutamate receptors, locus coeruleus, major depression, neurons, suicide.

Introduction
Major depressive disorder (MDD) and suicide are
outcomes of a complex interaction of neurochemistry,
environmental, genetic, and developmental factors. Retrospective studies indicate that nearly 80% of suicide victims suffered from depressive symptoms (Beskow, 1979;
Rich et al., 1986), thereby implicating depression as the
leading contributor to suicide. Most depressive episodes
and suicides are preceded by stressful events, such as adversity in early life (Mann and Currier, 2010). The major
noradrenergic tract, the dorsal bundle, arising in the
pontine nucleus locus coeruleus (LC) and innervating
the dorsal brain – including the neocortex and hippocampus – is a vital component of the stress response.

Address for correspondence: Dr G. A. Ordway, Department of Biomedical
Sciences, James H. Quillen College of Medicine, East Tennessee State
University, P.O. Box 70577, Johnson City, TN 37614, USA.
Tel.: +423 439 6346 Fax: +423 439 2280
Email: ordway@etsu.edu

In rodents, stress increases LC activity (Heinsbroek et al.,
1991; Melia and Duman, 1991; Kollack-Walker et al.,
1997; Curtis et al., 2002) and chronic stress depletes NE
in the LC and in its projection regions (Weiss et al., 1980).
Norepinephrine (NE)-depletion in humans with a history
of depression can re-induce depression (Berman et al.,
1999; Hasler et al., 2008). Treatment with antidepressants,
including selective serotonin reuptake inhibitors (SSRIs),
reduces LC activity, possibly as a consequence of increased extraneuronal NE action at presynaptic autoreceptors (Melia et al., 1992; Grant and Weiss, 2001;
West et al., 2009). Collectively, these studies indicate
that the LC has a major role in the origin of clinical
depression and possibly suicide.
A major, stress-sensitive excitatory input that intrinsically modulates LC activity is the amino acid transmitter,
glutamate. Glutamatergic inputs to the LC originate from
the paragigantocellularis nucleus, lateral habenula, and
prefrontal cortex (Herkenham and Nauta, 1979; AstonJones et al., 1986; Jodo and Aston-Jones, 1997). Recent
ﬁndings suggest that glutamatergic input to the LC may
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Table 1. Nomenclature for glutamate receptor genes that were studied, and their corresponding proteins
Genea

Proteinb

N-methyl-D-aspartate (NMDA) receptor subunits

GRIN1
GRIN2A
GRIN2B
GRIN2C
GRIN2D
GRIN3A
GRIN3B

GluN1, NMDAR1, NR1
GluN2A, NMDAR2A, NR2A
GluN2B, NMDAR2B, NR2B
GluN2C, NMDAR2C, NR2C
GluN2D, NMDAR2D, NR2D
GluN3A, NMDAR3A, NR3A
GluN3B, NMDAR3B, NR3B

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) glutamate receptor subunits

GRIA1
GRIA2
GRIA4

GluR-1, GluA1
GluR-2, GluA2
GluR-4, GluA4

Kainate glutamate receptor subunits

GRIK1
GRIK3
GRIK5

GluR-5, GluK1
GluR-7, GluK3
GluK5, KA2

Metabotropic glutamate receptor subunits

GRM4
GRM5
GRM8

mGluR4
mGluR5
mGluR8

a
b

Derived from the HUGO gene nomenclature committee responsible for designating unique gene names (Wain et al., 2002).
Ofﬁcial protein nomenclature showing both the recommended and alternative protein names (Uniprot, 2008).

be a key mediator of abnormal LC activity in depression.
Of particular interest is the lateral habenula, where electrical stimulation inhibits habenular activity, resulting in
a reduction of depressive behaviors, possibly in part
due to a reduction in glutamatergic activation of the LC
(Sartorius and Henn, 2007). Antagonists of the glutamate
NMDA receptor decrease LC activity (Murase et al., 1992)
and ketamine, an NMDA receptor antagonist, produces
a rapid antidepressant effect that persists for weeks in
humans (Zarate et al., 2006). In fact, a single brief infusion
of ketamine reduces suicide ideation within an hour,
and the effect persists up to 24 h (Price et al., 2009;
Diazgranados et al., 2010). Speciﬁc abnormalities, such
as increased extraneuronal glutamate levels (Sanacora
et al., 2004) and altered expression of glutamate related
genes (Chandley et al., 2013), have been demonstrated
speciﬁcally in depressed suicide victims. These ﬁndings
indicate that glutamatergic activation of the LC may be
abnormal in depression.
Glutamate signaling in the brainstem of both rodents
(Anon-Allen brain atlas) and non-human primates
(Noriega et al., 2007) is mediated by NMDA-, AMPA-,
and kainate-ionotropic receptors and G protein-coupled
metabotropic glutamate receptors. In vitro studies using
brain slice preparations indicate that signaling through
all glutamate receptor classes can activate LC neurons
(Olpe et al., 1989; Page et al., 2005). The current study
was undertaken to examine the expression of glutamate
receptor genes (see Table 1 for nomenclature) in human
LC neurons, and to determine if receptor gene expression
levels are altered in post-mortem brain tissue of depressed subjects, the majority of which died by suicide.
Given recent evidence of the rapid antidepressant properties of NMDA receptor antagonists in humans, we

evaluated the expression of all human NMDA receptor
subunit genes in the LC. For the remaining glutamate receptor genes, including the AMPA, kainate and metabotropic glutamate receptors, we examined only those
that demonstrated measurable gene expression in the
mouse LC, according to the Allen Brain Atlas (Lein
et al., 2007).
Methods
Brain tissue
Tissue for the described studies were obtained from
the following brain banks: Cleveland (22 subjects),
Pittsburgh (13 subjects), and Quebec Suicide Brain Bank
(one subject), as previously described (Chandley et al.,
2013). All specimens were obtained at autopsy in accordance with the respective Institutional Review Board
Protocol (IRB). Psychiatric assessment consisted of retrospective structured interviews with family members and
evaluation of previous medical records by trained clinicians. A post-mortem psychiatric diagnosis obtained in
this manner is considered to be comparable to the diagnosis of the living individual (Kelly and Mann, 1996;
Dejong and Overholser, 2009). Control and MDD subjects
were carefully matched prior to initiation of this study,
primarily according to age and gender. Because of the
limited number of control subjects available, perfect
matching of control–MDD subject pairs for all demographic variables was not possible. The matched pairs exhibited an overall mean age difference of 4.9 ± 0.8 yr
(S.E.M.; range 0–11 yr). Cigarette smoking was matched
when possible except for pair ﬁve, with smoking histories
unknown for two control subjects and one MDD subject.
The remaining factors, including post-mortem tissue
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Table 2. Subject demographics
Paira

Subject

Age

pH

RIN

PMI

Smoker

Toxicology

Tissue

M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F

17
46
48
27
59
58
18
72
54
47
18
58
43
49
42
18
37
74
54
74
45.7
4.1

6.71
6.95
6.98
6.88
6.79
6.78
6.60
6.30
6.50
6.10
6.40
5.80
7.00
7.10
6.70
7.00
6.47
6.62
6.52
6.60
6.64
0.07

7.40
6.76
7.40
8.40
7.65
7.67
7.90
7.30
6.50
8.30
6.40
6.40
7.40
8.50
7.40
8.70
7.30
6.70
7.70
7.00
7.44
0.15

24.0
19.0
9.0
17.0
6.0
21.0
16.0
16.4
26.3
25.0
31.5
27.0
22.3
19.9
23.5
14.6
17.0
21.0
19.0
24.9
20.0
1.4

No
No
Yes
Yes
No
Yes
Unknown
No
No
20 y ago
Unknown
No
No
Yes
No
No
No
Yes
Yes
No

Ethanol
Ethanol
NDD
NDD
Lidocaine
NDD
NDD
Diltiazem
Morphine
NDD
Midazolam
NDD
NDD
Doxylamine
Butalbital
Diazepam
NDD
NDD
Lidocaine
Diazepam

LC
LC
LC, Ctx
LC, Ctx
LC, Ctx
LC, Ctx
LC
LC
LC
Ctx
LC
LC
LC
LC
LC
LC
Ctx
Ctx
Ctx
LC

M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M

18
37
41
30
60
64
25
77
52
20
48
51
44
38
18
38
81
65
44.8
4.5

6.58
6.67
6.24
6.91
6.31
6.85
6.90
N/A
6.48
6.73
6.68
6.60
6.50
6.70
7.00
6.52
6.78
6.24
6.63
0.05

6.83
6.90
6.70
8.05
6.80
7.25
7.60
6.70
5.80
6.70
6.70
7.50
7.20
8.70
8.50
7.20
6.10
6.70
7.11
0.18

27.0
31.0
19.0
18.0
20.0
26.0
12.9
19.6
18.0
20.0
17.0
5.3
11.0
18.8
10.1
24.0
33.0
30.0
20.0
1.8

Unknown
No
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
Yes
No
No
No
Yes
Yes

CO
Ethanol
Chlorpheniramine
NDD
Ethanol
Ethanol
NDD
CO, Diazepam, Temazepam
CO
Diphenhydramine
NDD
Citalopram, Venlafaxine
NDD
NDD
Ethanol
NDD
NDD
Codeine

LC
LC
LC, Ctx
LC, Ctx
LC, Ctx
LC, Ctx
LC
LC
LC, Ctx
LC
LC
LC
LC
LC
LC
Ctx
Ctx
Ctx

pH, negative log10 of the hydrogen ion concentration; RIN, RNA integrity number generated by the Agilent 2100e; PMI, post-mortem
interval; NDD, no drugs detectable; y, years; LC, locus coeruleus; Ctx, cortex.
a
Pair numbers here indicate the same subject pair numbers that appear in the ﬁgures.
b
Denotes that different donor subjects were used in the two different brain areas (LC and cortex) for the same depressive subject. This
was necessary because tissue for both regions were not available from the same control subject.
c
Represents the controls that were used for the gene expression distribution study wherein RNA was extracted from trephine-punched
LC; KS85 was only used for the distribution study and was not used in gene expression studies comparing control to MDD subjects.

pH (Harrison et al., 1995), RNA integrity number (RIN),
post-mortem interval (PMI), and storage time in
freezer were matched as closely as possible (Table 2).
Tissues from matched pairs were always prepared and

biochemically analyzed simultaneously. All tissues had
a RIN value greater than 5.8, determined using an
Agilent Bioanalyzer 2100e (Ordway et al., 2009). Toxicological evaluations were conducted with blood and
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Normal control donors
1
KS57
2
KS59
3
KS21
4
FF1
5
KS31
6
KS23
7
KS78
8
KS74
KS67
9b
KS82
9b
10
KS63
11
KS65
12
KS70
13
KS72c
14
KS76c
15
KS80c
16
RR
17
KS27
18
VV
KS85c
MEAN
S.E.M.
Major depressed donors
1
KS58
2
KS56
3
KS12
4
GG1
5
KS32
6
KS24
7
KS79
8
KS75
9
DD
10
KS64
11
KS66
12
KS71
13
KS73
14
KS77
15
KS81
16
TT
17
KS28
18
WW
MEAN
S.E.M.

Gender
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Tissue preparation
At autopsy, blocks of tissue from the pontine LC
and Brodmann Area 10 (BA10) were frozen and stored
at −80 °C. Frozen tissue blocks were subsequently cut
at a 10 μm thickness with a cryostat microtome (Leica
CM3050 S) and mounted for histochemical analysis or
laser capture microdissection (LCM). Slides were placed
in a cold microslide box on ice and then transported to
−80 °C for storage up to 6 months. For the distribution
study, LC tissue was dissected from frozen tissue sections
using a 3 mm trephine punch and then homogenized for
biochemical analysis.
Staining and laser capture microdissection
Prior to sectioning, the knife holder and anti-roll plate
were carefully wiped with 100% ethanol to avoid crosscontamination between subjects. Sections (10 μm) for
LCM were mounted at room temperature (22 °C) on a
HistoGene® LCM microslides (Molecular Devices, USA)
and placed immediately in a chilled microslide box at
−20 °C. Noradrenergic and cortical neurons were identiﬁed from brain sections mounted on PEN-membrane
glass slides, stored at −80 °C, using the Histogene LCM
Frozen Section Staining Kit (Molecular Devices, USA).
This method has been described in detail (Ordway
et al., 2009). LCM was performed on an Arcturus
Veritas™ Microdissection Instrument; Model 704
(Molecular Devices, USA). This method has been described in detail (Ordway et al., 2009). Paired control
and MDD tissues were stained and subjected to LCM

sequentially within a 5 d time frame; less time was not
possible because of the time required to capture a sufﬁcient number of cells by LCM.
RNA preparation, ampliﬁcation, and polymerase
chain reaction (PCR)
Initially, we were interested in a quantitative assessment
of the amounts of gene expression of the different receptors. Homogenates of trephine-dissected LC tissues were
used to isolate RNA for these quantitative comparisons
because the number of laser captured neurons required
to do this was cost-prohibitive. Messenger RNA levels
for tissue homogenates (N = 4) were assessed by quantitative polymerase chain reaction (PCR) (Biorad, USA) to
determine relative receptor/receptor subunit levels in LC
neurons. Each 18 μl PCR reaction for the receptor/subunit
genes GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIA1,
GRIA2, GRIA4, GRM5 and GRIK5 contained 1.5 μl of
cDNA, 9 μl of Platinum Supermix (Invitrogen), 250 nM
sense and antisense primer (Integrated DNA Technologies, USA), 1.5 mM Mg2+ (Life Technologies, USA), and
SYBR Green (Life Technologies, USA). Quantitative PCR
reactions for GRM4, GRM8, GRIK1, and GRIK3 consisted
of Fast SYBR mix 10 μl (KAPA), 250 nM sense and antisense
primer (Integrated DNA technologies, USA) and 1 μl
cDNA. Optimal reaction temperatures and primer efﬁciencies were determined for each primer set using a matching synthetic standard oligonucleotide. Subsequently,
oligonucleotide standards were used to determine copy
numbers of all gene transcripts. Receptor/subunit gene
transcripts were normalized using the geometric mean
of the two reference genes (TATA and GAPDH). Genes
and primers are shown in Supplementary Table 1.
Because very small amounts of RNA are available
with samples collected by LCM, end-point PCR was
used to quantify transcripts from laser capture neurons
to determine gene expression differences between control
subjects and MDD subjects as described previously
(Ordway et al., 2009). Total RNA was extracted from
laser captured cells using the RNA aqueous system optimized for LCM according to the manufacturer’s instructions (Life Technologies, USA). Genomic DNA was
removed from each sample by DNAase I treatment at
37 °C followed by a gel-based removal of enzyme (Life
Technologies, USA). RNA was reverse transcribed to
cDNA using the Superscript III ﬁrst strand synthesis
system primed with a mix of oligo(dT)20 and random
hexamers (Life Technologies, USA) and stored at −20 °C
until use. Target gene expression from end-point PCR
was normalized to the geometric mean of three reference
genes (GAPDH, ACTB, and UBC). RNA preparation was
performed simultaneously for each paired control and
MDD sample. PCR reactions of paired samples were performed in triplicate at the same time in the same apparatus, and were analyzed on the same chip using the
Agilent Bioanalyzer.
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urine on all subjects to conﬁrm medical treatment, as well
as an index of drug and alcohol use or abuse at the time of
death.
Brain tissues were obtained from 20 psychiatrically
normal controls and 18 subjects diagnosed with MDD
at time of death (Table 2). All control subjects were void
of any previous major psychiatric illness. While two control and three MDD subjects had a history of alcohol use/
abuse, none had active alcohol abuse at the time of death.
Also, six control subjects and eight MDD subjects were
smokers at the time of death. No subject in the control
or MDD group had a history of other substance abuse,
and there was no evidence of substance use at the time
of death, as conﬁrmed by toxicology analysis; antidepressant medication was evident in the blood of one MDD
subject. Control subjects died by heart disease (8), gunshot (1), trauma (4), peritonitis (1), asthma (1), aneurysm
(1), distended aorta (1), pulmonary embolism (1), subarachnoid hemorrhage (1), and acute hemorrhage (1).
MDD subjects dying by suicide included those that died
by self-inﬂicted gunshot (8), hanging (2), CO poisoning
(3), unspeciﬁed suicide (1), and drowning (2). Two
subjects in the MDD group died from heart disease.
Comorbidities and causes of death have been excluded
from Table 2 to protect subject identity.

Elevated glutamate receptor gene expression in MDD 1573
GRIN2A, GRIN2B, GRIN2D, GRIA2, and GRIA4; low expression levels were found for the remaining glutamate
receptor genes. A comparison of expression levels of
glutamate receptor genes in mouse LC (Allen Brain
Atlas (http://mouse.brain-map.org/); Lein et al., 2007)
and human LC obtained in the present study (Fig. 1) is
shown in Table 3. Details of statistical comparisons of
gene expression levels amongst the various receptor subtypes appears in Supplementary Table 2.

GRIN1
GRIN2A
GRIN2B
GRIN2C
GRIN2D
GRIN3A
GRIN3B
GRIA1
GRIA2
GRIA4

Glutamate receptor/subunit gene expression in MDD

GRIK1
GRIK3
GRM4
GRM5
GRM8
0.0

0.2

0.4

0.6

1.5 2.0

Target/Ref(GM)
Fig. 1. Average gene expression levels of glutamate receptors/
subunits in punch-dissected locus coeruleus (LC) of control
subjects, as assessed by real time quantitative polymerase chain
reaction (n = 4). All primers are provided in Supplementary
Table 1. Target gene expression was normalized to the
geometric mean of two reference genes (GAPDH and TATA)
determined in the same samples.

Statistical analysis
End-point PCR analyses of each receptor subtype from
LC neurons captured by LCM were analyzed by paired
Student’s t-test using amplicon amounts normalized to
the geometric mean of the reference genes. Donors were
paired prior to laboratory experimentation (see Brain
Tissue section above for more information). Percentage
differences between matched control and MDD subjects
were computed and reported as the mean±S.E.M. Possible
relationships between post-mortem variables and levels
of gene expression were evaluated using Pearson’s correlation analyses. Linear correlations were performed to
ensure that demographic variables did not alter statistical
ﬁndings. Statistical analyses were performed using IBM
SPSS Statistics (version 21) and GraphPad Prism 5.0
(GraphPad Software Incorporated, USA) using a p < 0.05
as the signiﬁcance level.

Results
Levels of glutamate receptor gene expression in the
human LC region
Quantitative levels of the gene expression of glutamate
receptors and receptor subunits in the LC from four
control subjects is shown in Fig. 1. Of the 16 glutamate
receptor genes observed, GRIN1 exhibited the highest expression. Intermediate expression levels were found for
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GRIK5

The expression level of each reference gene in captured
LC neurons (normalized to the geometric mean of the
other two reference genes) was not signiﬁcantly different
comparing control to MDD subjects (Supplementary
Fig. 1), conﬁrming the stability of these gene expressions
across the two study groups. Gene expression levels
for the NMDA receptor subunits GRIN2B and GRIN2C
were, respectively, elevated in LC neurons by 148 ± 11%
(p < 0.001) and 134 ± 7% (p < 0.005; mean±S.E.M.) in MDD
subjects vs. matched normal control subjects (Fig. 2a, b).
Although the entire study was conducted in a matched
pair design (see Methods), the results of an independent
t-test are provided for the reader in Supplementary
Table 3 which shows similar statistical results for the comparison of control and MDD groups (GRIN2B, p = 0.003;
GRIN2C, p = 0.061).
In contrast, expression levels for genes for other
NMDA receptor subunits (GRIN1, GRIN2A, GRIN2D,
GRIN3A; Supplementary Fig. 2A–D), for the ionotropic
AMPA receptor subunits (GRIA1, GRIA2, GRIA4;
Supplementary Fig. 3A–C), and kainate receptor subunits
(GRIK1, GRIK3, GRIK5; Supplementary Fig. 3D–F) were
not signiﬁcantly different comparing MDD and control
subjects. Percentage differences in expression levels of
MDD vs. matched control subjects for these additional
ionotropic glutamate receptor genes were (in percentage
of controls) 109 ± 8 (GRIN1), 107 ± 9 (GRIN2A), 101 ± 8
(GRIN2D), 122 ± 38 (GRIN3A), 92 ± 7 (GRIA1), 96 ± 5
(GRIA2), 103 ± 6 (GRIA4), 96 ± 4 (GRIK1), 103 ± 11
(GRIK3), and 102 ± 7 (GRIK5).
Expression levels of genes for metabotropic receptors
mGluR4 and mGluR5 (GRM4 and GRM5) were signiﬁcantly higher in LC neurons from MDD subjects vs.
matched control subjects (Fig. 2c, d), although the magnitude of the difference between MDD and control subjects
for GRM4 was small. Amplimer amounts in MDD subjects as a percentage of matched controls were 116 ± 5
(GRM4; p < 0.01) and 145 ± 9 (GRM5; p < 0.0005). GRM8 expression levels (i.e. 106 ± 3%) were similar in MDD and
matched control subjects (Supplementary Fig. 2E). Comparison of gene expression levels between controls and
MDD groups using an independent t-test showed similar
results for GRM5 expression (p = 0.000), but GRM4
expression was not signiﬁcantly different (p = 0.103; Supplementary Table 3).
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Table 3. Expression levels of glutamate receptor genes, determined using RNA from punch-dissected locus coeruleus (LC) tissue from
four control subjects

Glutamate receptor name

Expression level determined
from Allen Brain Atlas (mouse)a

Expression level determined
by qPCR (human)

GRIN1
GRIN2A
GRIN2B
GRIN2C
GRIN2D
GRIN3A
GRIN3B
GRIA1
GRIA2
GRIA4
GRIK1
GRIK3
GRIK5 (KA2)
GRM4
GRM5
GRM8

Ionotropic NMDA 1
Ionotropic NMDA 2A
Ionotropic NMDA 2B
Ionotropic NMDA 2C
Ionotropic NMDA 2D
Ionotropic NMDA 3A
Ionotropic NMDA 3B
Ionotropic AMPA 1
Ionotropic AMPA 2
Ionotropic AMPA 4
Ionotropic, kainate 1
Ionotropic, kainate 3
Ionotropic, kainate 5
Metabotropic 4
Metabotropic 5
Metabotropic 8

+++b
−−
++
−−
−−
+++
−−
+
+++
+++
+++
++
++
++
+++
++

++++
++
++
+
++
+
−−
+
+++
+++
+
+
++
+
++
++

a

As determined using the Allen Brain Atlas, http://mouse.brain-map.org/, Lein et al. (2007).
Five levels of density ranking of gene expressions were qualitatively assessed as follows: ++++, Very high levels; +++, High levels;
++, Intermediate levels; +, Low levels; −− Undetectable by method.

b

(b)
1
2
3
4
5
6
8
9
10
11
13
14

Control–MDD pair

Control–MDD pair

(a)

p=0.0007
0

1

1
2
3
4
5
6
8
9
10
11
13
14

3

2

p=0.002
0

1

(c)

3

(d)
2
5
6
7
8
9
10
11
12
13
14
15
0.0

Control–MDD pair

Control–MDD pair

2

GRIN2C/Reference(GM)

GRIN2B/Reference(GM)

p=0.005
0.5

1.0
GRM4/Reference(GM)

1.5

2.0

1
2
3
4
5
6
7
8
9
12
13
14
15
0.0

p=0.0001
0.2

0.4
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Fig. 2. Statistically signiﬁcant gene expression changes of glutamate receptors or receptor subunits in LC neurons laser captured
from psychiatrically normal controls (slashed bars) and subjects with major depressive disorder (MDD) (solid bars). Each
control-MDD pair is identiﬁable by a distinct number on the y-axis that is consistent throughout the study. Expression of GRIN2B
(N = 12), GRIN2C (N = 12), GRM4 (N = 12), and GRM5 (N = 13) was normalized to geometric mean (GM) of three reference genes
(GAPDH, UBC, ACTB). Signiﬁcance levels are indicated in the bottom right corner of each panel.
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Fig. 3. Gene expression of glutamate receptors or receptor subunits in pyramidal neurons laser captured in frontal cortex, BA10,
from psychiatrically normal controls (slashed bars) and subjects with major depressive disorder (solid bars). Target gene expression
(GRIN2B N = 8; GRIN2C N = 8; GRM4 N = 8; and GRM5 N = 8) was normalized to the geometric mean (GM) of three reference genes
(GAPDH, UBC, and ACTB). No signiﬁcant changes were identiﬁed.

Glutamate receptor subunit gene expression in
prefrontal cortex BA10
To determine if MDD-associated abnormalities in gene
expression of glutamate receptors observed in the LC
were common to brain neurons, gene expression levels
were examined in pyramidal neurons captured by laser
microdissection from prefrontal cortex (BA10). Reference
gene comparisons between controls and MDD subjects revealed no signiﬁcant differences (Supplementary Fig. 4).
In contrast to LC neurons, no differences in expression
levels of GRIN2B, GRIN2C, GRM4 or GRM5 were
observed in pyramidal neurons from prefrontal cortex
comparing MDD to control subjects (Fig. 3a–d). An independent t-test of cortical pyramidal neuron data yielded
similar statistical ﬁndings (Supplementary Table 4).

Discussion
The present laser capture study demonstrates elevated
expression levels of genes encoding speciﬁc ionotropic
NMDA receptor subunits and speciﬁc metabotropic
receptors in LC noradrenergic neurons of MDD subjects
relative to psychiatrically normal control subjects. This
study focused on single cell-type analysis of MDD

pathology and extends the work of a previous study
that investigated an admixture of cells wherein elevated
protein levels of the NR2C subunit were observed in a
multi-cell type admixture of LC tissue from MDD subjects
(Karolewicz et al., 2005). In addition, we previously reported reduced expression of excitatory amino acid transporters in astrocytes surrounding the LC in MDD subjects
(Chandley et al., 2013). Together, these ﬁndings provide
strong support to the hypothesis that MDD is associated
with disrupted communication between glutamatergic
and noradrenergic LC neurons.
The present study is the ﬁrst to extensively characterize
the relative gene expression levels of glutamate receptors
and their subunits in the human LC. In addition to the
highly expressed NR1 NMDA subunit (GRIN1), we
found moderate gene expression levels of NR2A
(GRIN2A), NR2B (GRIN2B), NR2D (GRIN2D) subunits
and low levels of NR2C (GRIN2C) and NR3A (GRIN3A)
subunits. The functional NMDA receptor complex is
made of a glycine binding NR1 subunit combined with
at least one of the other glutamate binding NR2 or NR3
subunits. Although, permeable to both potassium and calcium, calcium is essential in activating the PI3K and
CREB cell-signaling pathways that distinguish the
NMDA family of receptor signaling from the other
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Limitations
There are limitations in the present study that should be
considered. We were unable to examine protein levels
for each receptor that exhibited elevated gene expression
levels. As noted above, our laboratory has previously

shown elevated NR2C subunit immunoreactivity in
homogenized tissue punches of the LC in MDD subjects,
most of which died by suicide (Karolewicz et al., 2005).
In the same study, NR2B immunoreactivity was below
levels that permitted quantiﬁcation in the LC. At least
for the measurable NR2C subunit, the present ﬁndings
imply that elevated NR2C protein found in the previous
study (which utilized LC homogenates containing
multiple cell types) occurs on noradrenergic neurons in
the LC. However, it remains possible that NR2C subunit
protein expressed on glial cells could be similarly elevated in MDD, since the present study did not examine
glutamate receptor gene expression on glia in the LC.
The generally low expression levels of G-protein-coupled
glutamate receptors, e.g. mGluR4, mGluR5, mGluR8, in
the brain, does not permit quantiﬁcation of protein levels
in extremely small tissue samples typical of LC collection
methods. There are not currently available antibodies for
glutamate receptors that are adequate for quantitative
immunolabelling of frozen human post-mortem brain
sections.
The increase in GRIN2C expression (present study) and
increase in NR2C protein levels (Karolewicz et al., 2005)
in the LC of MDD subjects was not accompanied by increases in GRIN1 expression (present study) and protein
expression of the NR1 subunit of the NMDA receptor
(Karolewicz et al., 2005). The NR1 subunit is a mandatory
subunit of the multi-subunit NMDA receptor complex.
Hence, our ﬁndings do not support the concept of more
NMDA receptors in MDD, but a possible change in the
subunit composition, and thereby the ionotropic properties, of the NMDA receptor in MDD.
Finally, all but two MDD subjects died by suicide.
Hence, we are unable to statistically evaluate the possible
association of gene expression abnormalities speciﬁc
for MDD but separate from suicide. It can be noted that
in every instance, the expression levels of GRIN2B,
GRIN2C, GRM4 and GRM5 in LC neurons of the two nonsuicide MDD subjects were higher than the paired normal
control subjects.
Conclusion
Numerous studies in humans and laboratory animals
indicate that MDD is associated with elevated glutamatergic activity. A variety of factors (psychological stress,
magnesium deﬁciency, oxidative stress, inﬂammation,
bioenergetic dysfunction) associated with depression are
known to activate NMDA receptor signaling (Marsden,
2011). The present study contributes to growing evidence
of altered glutamatergic input to the noradrenergic LC in
MDD (Karolewicz et al., 2005; Miguel-Hidalgo et al.,
2010; Chandley et al., 2013). Drugs that target NMDA
and mGluR receptors are known to exert antidepressant
effects in both humans and animals (Zarate et al., 2006;
Dhir and Kulkarni, 2008; Muhonen et al., 2008; Krystal
et al., 2011). It seems reasonable to suggest that at least
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ionotropic glutamate receptors (Lonze and Ginty, 2002;
Papadia et al., 2005). This is particularly intriguing since
we observed elevations in NMDA receptor subunit gene
expressions in MDD, but no gene expression changes
in the moderately expressed GluA1 receptor (GRIA1)
or the highly expressed GluA2 (GRIA2) and GluA4
(GRIA4) of the AMPA ionotrophic family, nor in any of
the receptor subunits (GRIK1, GRIK3, GRIK5) from the
kainate ionotrophic class of receptors. If altered NMDA
receptor subunit gene expression is secondary to elevated
glutamate input to the LC, as has been presumed
based on post-mortem indices of glutamatergic activity
(Chandley et al., 2013), one might have expected to
ﬁnd alterations in other subtypes of ionotropic receptors
on LC neurons. Since increases in gene expression
were only identiﬁed in the NMDA family of inotropic
glutamate receptors, gene expression of these subunits
may be uniquely susceptible to elevated glutamatergic
input. Alternatively, altered expression may be a fundamental pathology of LC neurons unrelated to any
MDD-associated abnormalities in glutamatergic input. It
is noteworthy that LC neurons are initially activated by
glutamate via the NMDA receptor, followed by a postactivation inhibition mediated by glutamate’s action
at a kainate/AMPA potassium-gated channel (Zamalloa
et al., 2009). It is conceivable that an elevation of
NMDA receptors (or a change in their activity; see
below) without any changes in kainate/AMPA receptors
may result in greater or more sustained excitability of
noradrenergic neurons in MDD.
Expression of three metabotropic glutamate receptor
genes (GRM4, GRM5, GRM8) has previously been
demonstrated in the nonhuman primate LC (Noriega
et al., 2007) and the present study conﬁrmed their expression in the human LC. These three metabotropic receptors belong to two subclasses of G-protein coupled
metabotropic glutamate receptors (mGluRs) and utilize
different signaling pathways. Group I mGluRs
(mGluR5, GRM5) are Gαq-linked to initiate phospholipase
C and the diacylglycerol signaling pathways; Group II
(mGluR4 [GRM4] and mGluR8 [GRM8) are Gαi/o-linked
to inhibition of the cAMP pathway (as reviewed by
(Conn and Pin, 1997). Our studies identiﬁed a robust
increase in expression levels of GRM5, but not GRM8,
in LC neurons from MDD subjects in comparison to normal control subjects. A small, but statistically signiﬁcant,
increase in GRM4 expression levels was also observed.
Interestingly, negative allosteric modulators of mGluR5
have antidepressant efﬁcacy in rodent models (Hughes
et al., 2013).
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